Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on Thyroid Eye Disease (TED), a condition where the eyes become swollen and may bulge forward. The study will test a new medication called VRDN-001, which is a type of antibody that targets a specific receptor in the body called IGF-1 receptor. The purpose is to determine if this treatment is safe and effective for people who have had TED for a long period (chronic form of the disease).

The treatment involves receiving five intravenous infusions of either VRDN-001 or placebo over several weeks. The medication will be given through a vein using a solution that contains sodium chloride (normal saline). Each infusion will be carefully prepared to contain the correct amount of medication based on the person's weight.

During the study, doctors will measure changes in eye bulging (also called proptosis) and other eye-related symptoms. They will also monitor how well participants tolerate the treatment and track any side effects that may occur. The total duration of participation in the study will be approximately 12 weeks, during which participants will need to attend regular check-ups at the clinic.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Your eye condition (thyroid eye disease) will be evaluated, including measurements of eye bulging (proptosis).

    Basic health checks and tests will be performed to confirm your eligibility for the study.

  2. Step 2

    Treatment assignment

    You will be randomly assigned to receive either VRDN-001 or a placebo treatment.

    Neither you nor your doctor will know which treatment you are receiving during the study.

  3. Step 3

    Treatment period

    You will receive 5 intravenous infusions of either VRDN-001 (10 mg/kg) or placebo.

    The medication will be given through a vein in your arm (intravenous infusion).

    Your eye measurements and symptoms will be monitored throughout the treatment period.

  4. Step 4

    Follow-up evaluation

    Three weeks after your fifth infusion, your eye measurements will be taken again.

    Your eye symptoms will be evaluated, including any improvements in double vision (diplopia).

    The medical team will assess your overall response to the treatment at week 15.

    Any side effects or health changes will be recorded throughout the study period.

  5. Step 5

    Final assessment

    Your final eye measurements will be taken to compare with your initial measurements.

    The medical team will evaluate the overall effectiveness of the treatment.

    All health changes and side effects will be documented for final safety assessment.

Who can join the trial?

7 criteria

  • Age between 18 and 75 years old
  • Must have been diagnosed with thyroid eye disease (TED) of any severity level, as measured by a special scoring system called CAS scale
  • Must have moderate to severe chronic thyroid eye disease with eye bulging (proptosis) of at least 3 millimeters and more than 17 millimeters when measured before starting treatment
  • Eye-related symptoms or signs must have started more than 15 months before the study screening
  • Must agree to use reliable birth control methods as detailed in the study protocol
  • Female participants must have a negative pregnancy test during the screening visit
  • Both men and women can participate in the study

Who cannot join the trial?

15 criteria

  • Age under 18 or over 65 years old
  • Currently pregnant or breastfeeding women
  • Previous treatment with orbital radiotherapy (radiation therapy directed at the eye area)
  • Active eye infection or severe eye inflammation
  • History of orbital decompression surgery (surgery to reduce pressure in the eye socket) in the past 3 months
  • Uncontrolled thyroid function (too high or too low thyroid hormone levels)
  • Severe heart, liver, or kidney disease
  • Active or recent cancer within the past 5 years
  • Current smoking or tobacco use
  • Use of other investigational drugs within 30 days before starting the study
  • History of substance abuse in the past 2 years
  • Severe psychiatric conditions that could interfere with study participation
  • Known allergies to study medication or its components
  • Inability to provide informed consent
  • Participation in another clinical trial
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • VRDN-001

    is a humanized monoclonal antibody that targets the IGF-1 receptor. This medication is given through infusions and is being studied for treating chronic thyroid eye disease (TED). It works by binding to specific receptors that are involved in the eye inflammation and swelling associated with thyroid eye disease. This targeted approach aims to reduce the symptoms and progression of the condition.

  • Placebo

    is an inactive substance that contains no medication. It is used as a comparison to determine if VRDN-001 is effective in treating thyroid eye disease.

What is already known about the treatment

VRDN-001 - A humanized monoclonal antibody administered through intravenous infusion that targets the IGF-1 receptor for the treatment of chronic thyroid eye disease (TED). This investigational medication is currently being studied in clinical trials to evaluate its safety, tolerability, and effectiveness in patients with TED, where it works by blocking the IGF-1 receptor to potentially reduce inflammation and tissue changes in the eyes. As a biological therapy, VRDN-001 belongs to the class of targeted immunotherapy drugs, and is administered as a series of five infusions at a dosage of 10 mg/kg of body weight.

Investigated diseases

Thyroid Eye Disease - A condition that affects the eyes and surrounding tissues, typically associated with thyroid disorders. The disease causes inflammation and swelling of the muscles and fatty tissues around the eyes, leading to various eye symptoms. The affected tissues behind the eyes become inflamed and enlarged, which can push the eyeballs forward, causing bulging eyes (proptosis). As the disease progresses, patients may experience eye irritation, pressure sensation, and problems with eye movement. In some cases, the condition can cause double vision (diplopia) due to the affected eye muscles not working properly together.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-507217-10-00Protocol codeVRDN-001-301Estimated enrolment290 patientsSponsorViridian Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.